Cooperative Agreement U24HL135691

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $3,125,882 Cooperative Agreement (CFDA 93.837 - Cardiovascular Diseases Research) to New England Research Institutes Inc. (NERI) to serve as the Data Coordinating Center (DCC) for the Pediatric Heart Network (PHN) from January 1, 2025 to December 31, 2031. As the DCC, NERI will provide robust scientific oversight, logistical support, and infrastructure for the PHN. Key responsibilities include project management, study coordination,...

This Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $400,000 to The Children's Hospital of Philadelphia (CHOP) to establish the PKDNET - ARPKD Learning Network. The objective is to accelerate clinical trials for autosomal recessive polycystic kidney disease (ARPKD) by creating a robust data resource to identify a research-ready cohort of children with ARPKD and collect high-quality natural history data. This will help define clinical...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $168,480 to Ann & Robert H. Lurie Children's Hospital of Chicago to study how prenatal care utilization pathways impact postnatal healthcare outcomes for publicly insured children with congenital heart defects (CHDs). The key objectives are to: 1) identify common prenatal care utilization pathways leading to delivery at a CHD surgical...

This Cooperative Agreement award, with a total funding amount of $650,398.00, was provided by the National Center on Birth Defects and Developmental Disabilities, part of the Centers for Disease Control and Prevention (CDC), under the Disabilities Prevention Federal Grant Program (CFDA 93.184). The award aims to advance the surveillance of congenital heart defects (CHD) by utilizing informatics and data science approaches to improve the health of children, adolescents, and adults living with...

This $1,000,000.00 Cooperative Agreement award from the National Center on Birth Defects and Developmental Disabilities (part of the U.S. Department of Health and Human Services) provides funding for the "Surveillance of Congenital Heart Defects Among Children, Adolescents and Adults (Component A)" program under the Disabilities Prevention (CFDA 93.184) federal grant program. The primary products or services to be delivered through this 5-year award, from September 30, 2024 to...

The National Center on Birth Defects and Developmental Disabilities, a division of the Centers for Disease Control and Prevention (CDC), awarded a $1,498,368 Cooperative Agreement to Duke University on September 30, 2024 for the "North Carolina Congenital Heart Disease Surveillance Network" project. This 5-year award (through September 29, 2029) is funded under the CDC's Disabilities Prevention program (CFDA 93.184), which supports national efforts to reduce health disparities and...

This $6,305,599 Cooperative Agreement award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) funds the establishment of a Data Coordinating and Operations Center (DCOC) for the NIH Environmental Influences on Child Health Outcomes (ECHO) IDEA States Pediatric Clinical Trials Network (ISPCTN). The primary objectives are to facilitate the development, conduct, and dissemination of multi-center pediatric clinical trials...

This federal Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) provides $812,343 to test the efficacy of teleconsultation in reducing serious safety events during prehospital care for critically ill infants and children. The award funds a multicenter, simulation-based randomized controlled trial to compare the impact of teleconsultation with pediatric emergency physicians (using video)...

The Duke University has been awarded a $1,220,496 Cooperative Agreement from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837). The award will fund the U.S. portion of the randomized LEADER-PAD trial, which aims to assess whether low-dose colchicine can reduce the risk of cardiovascular and limb-related outcomes in patients with peripheral artery disease (PAD). The award will support the establishment of a...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,428,701 to the University of Missouri at Kansas City (UMKC) to conduct a prospective, multi-site study of 1,000 pregnant individuals with cardiovascular disease. The study aims to identify patient characteristics and structural care factors associated with adverse pregnancy outcomes, maternal cardiovascular events, and...